We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > inrebic

News List

Bristol Myers Squibb revenues increase in Q1 2021 pharmaceutical-technology
May 06, 2021
Bristol Myers Squibb has reported revenues of $11.1bn for the first quarter of this year, which represents an increase of 3%, compared to $10.78bn in the first quarter last year.
FDA approves INREBIC for Myelofibrosis treatment biospectrumasia
August 20, 2019
Celgene Corporation has announced the U.S. Food and Drug Administration (FDA) has approved INREBIC® (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocyt
FDA Approves Inrebic Capsules for Myelofibrosis drugs
August 19, 2019
Inrebic (fedratinib) capsules have been approved to treat adults with intermediate-2 or high-risk primary or secondary myelofibrosis, making it the second drug approved to treat patients with this disease...
FDA Approves Inrebic (fedratinib) for the Treatment of Patients With Myelofibrosis drugs
August 19, 2019
Celgene Corporation announced the U.S. Food and Drug Administration (FDA) has approved Inrebic (fedratinib) for the treatment of adult patients with intermediate-2 or high-risk primary or ...